Finland· FI-REL-REL60694
Rosuvastatin/Ezetimib Krka
A rosuvastatin and ezetimibe product containing rosuvastatin calcium + ezetimibe, registered in Finland by KRKA d.d. Novo mesto. The same ATC class is registered in 9 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Rosuvastatin and ezetimibe is registered in 9 of 19 countries.
Countries holding a registration under ATC C10BA06 (rosuvastatin and ezetimibe), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Rosuvastatin and ezetimibe · ATC C10BA06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Rosuvastatin calcium + Ezetimibe
- Manufacturer
- KRKA d.d. Novo mesto
- Country
- Finland (FI)
- ATC code
- C10BA06
- ATC class
- Rosuvastatin and ezetimibe
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rosuvastatin and ezetimibe in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDELIPID PLUSEgis Pharmaceuticals PLC, Budapešť
- SpainALZIL PLUS 10 MG/10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAFerrer Internacional S.A.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- PolandCorosweraKrka, d.d., Novo mesto
- NetherlandsEklipo 10 mg/10 mg filmomhulde tablettenMedicair Bioscience Laboratories CY Limited
- SwitzerlandEzetimib Rosuvastatin axapharm
- FranceLIPOROSA 10 mg/10 mg, géluleBB FARMA (ITALIE)
- NorwayRostezeEQL Pharma AB
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Arosuva Plus Ezetimib, Ezerosu
- Belgium · Cholecomb, Ezetimibe/Rosuvastatin Sandoz
- Bulgaria · Rosteza 10 Mg/10 Mg, Rosteza 20 Mg/10 Mg
- Cyprus · Celmantin Plus, Lipocomb
- Czechia · Delipid Plus, Refidoro
- Germany · Antilia, Ezehron Duo
- Estonia · Delipid Plus, Rosazimib
- Spain · Alzil Plus, Arrox Plus
- France · Liporosa, Quiloga
- Greece · Celmantin Plus, Co-Rosuvador
- Croatia · Arosen, Co-Roswera
- Hungary · Co-Xeter, Delipid Plus
- Ireland · Lipocomb, Rosuvastatin/Ezetimibe Krka
- Italy · Aurozeb, Cholecomb
- Lithuania · Roselia, Sorvitimb
- Luxembourg · Cholecomb, Myrosor
- Latvia · Rosazimib, Rosulip
- Malta · Ezehron Duo, Lipocomb
- Netherlands · Ayadont, Cholecomb
- Norway · Rosteze, Rosuvastatin/Ezetimib Krka
- Poland · Coroswera, Ezehron Duo
- Portugal · Colroset, Lipocomb
- Romania · Co-Roswera, Lipocomb
- Slovenia · Refidoro, Rozor
- Slovakia · Lipocomb, Rosazimib
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/54145ab2-e2ec-4106-ab9c-bca90d1911ec GET /v1/drugs/54145ab2-e2ec-4106-ab9c-bca90d1911ec?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "ED",
"strength": "20 mg / 10 mg",
"atc_label": "rosuvastatiini ja etsetimibi",
"ma_number": "41633",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL60694",
"authorised_at": "2024-01-26"
}See everything about rosuvastatin and ezetimibe.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.